The Use of Alefacept in the Treatment of Psoriasis

Abstract

Get full access to this article

View all access options for this article.

References

Krueger

Callis

. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49:S87–S97.

Mrowietz

. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001; 26:362–367.

Callen

Kruger

Lebwohl

. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003; 49:897–899.

Krueger

. Selective targeting of T-cells subsets: Focus on alefacept-a remitting therapy for psoriasis. Expert Opin Biol Ther 2002; 2:431–441.

Prinz

. The role of T-cells in psoriasis. J Eur Acad Dermatol Venereol 2003; 17:257–270.

Ellis

Krueger

. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248–255.

Lebwohl

Christophers

Langley

. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139:719–727.

Gordon

Langley

. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003; 2:494–500.

Langley

Baker

Roberts

. The safety of alefacept using a reduced schedule for monitoring T-cells. J Am Acad Dermatol 2004; 50:152.

10.

Lebwohl

. Combining the new biologic agents with our current psoriasis armamentarium. J Am Acad Dermatol 2003; 49:S118–S124.

11.

Koo

. Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis. Presented at International Psoriasis Symposium, June 18–22, 2003, New York.

12.

Ortonne

Khemis

. Combination therapy with alefacept plus narrowband ultraviolet B light for treatment of psoriasis. Presented at International Psoriasis Symposium, June 18–22, 2003, New York.